[Ip-health] KEI Comments Regarding NIH Exclusive License on Gene Therapy to Treat Ocular Disease

Claire Cassedy claire.cassedy at keionline.org
Mon Jan 13 11:36:03 PST 2020


https://www.keionline.org/32116

KEI Comments Regarding NIH Exclusive License on Gene Therapy to Treat
Ocular Disease
Posted on January 13, 2020 by KEI Staff

On Friday January 10, 2020, Knowledge Ecology International (KEI) submitted
comments to the National Institutes of Health (NIH) regarding the
“Prospective Grant of an Exclusive Patent License: Gene Therapy for Ocular
Disease” to OcQuila Therapeutics, Ltd. (84 FR 65169) [1]. The technology to
be licensed involves an adeno-associated virus (AAV) gene therapy that has
already undergone a Phase I/II clinical trial sponsored by the NIH.

As KEI’s comments assert, given the technology’s relatively advanced
research and development stage, the regulatory incentives the licensee is
likely to receive, the government’s investment in the technology, and the
price that OcQuila likely will be able to charge for the treatment, the NIH
should negotiate a license with terms that are favorable to the public.

PDF versions of KEI’s full comments on the proposed exclusive license and
accompanying attachments are available here:

- KEI Comments Prospective Grant of Exclusive Patent License Gene Therapy
for Ocular Disease:
https://www.keionline.org/wp-content/uploads/1.10.2020-KEI-Comments-Prospective-Grant-of-Exclusive-Patent-License-Gene-Therapy-for-Ocular-Disease.pdf
- Attachment A:
https://www.keionline.org/wp-content/uploads/Attachment-A-10Jan2020.pdf
- Attachment B:
https://www.keionline.org/wp-content/uploads/Attachment-B-10Jan2020.pdf
- Attachment C:
https://www.keionline.org/wp-content/uploads/Attachment-C-10Jan2020.pdf


[1]
https://www.federalregister.gov/documents/2019/11/26/2019-25685/prospective-grant-of-an-exclusive-patent-license-gene-therapy-for-ocular-disease


More information about the Ip-health mailing list